Stockscreener 앱 받기
5.32
4.15%
-0.22
전일 마감가:
$5.54
열려 있는:
$5.37
하루 거래량:
487.22K
Relative Volume:
0.43
시가총액:
$264.92M
수익:
-
순이익/손실:
$-122.31M
주가수익비율:
-1.1783
EPS:
-4.5151
순현금흐름:
$-110.41M
1주 성능:
+0.00%
1개월 성능:
+1.14%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.20
$5.47
1주일 범위
$5.05
$5.55
52주 변동 폭
$4.29
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.3097 | 276.41M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.26 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.09 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.91 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | TD Cowen | Buy |
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Helus Pharma Inc 주식(HELP)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Jefferies reiterates Helus Pharma stock rating on anxiety data - Investing.com
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - The Manila Times
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - citybuzz -
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com South Africa
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - ChartMill
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Helus Pharma Inc. (HELP) News, Articles, Events & Latest Updates - Stocktwits
Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board - Fierce Biotech
Helus Pharma adds Langer, Brannan to scientific advisory board By Investing.com - Investing.com India
Helus Pharma Adds Langer and Brannan to Advisory Board to Bolster Late-Stage Mental Health Pipeline - TipRanks
Helus Pharma (Nasdaq: HELP) adds Langer and Brannan to scientific board - Stock Titan
Helus Pharma adds Langer, Brannan to scientific advisory board - Investing.com
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan - The Manila Times
How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st
Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money
Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India
Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks
Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan
Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan
Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus
Helus Pharma Brd Starts Process to Find Permanent CEO >HELP - Moomoo
Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com
Helus Pharma Says Eric So To Resume Role As Interim Chief Executive Officer - TradingView
Helus Pharma welcomes White House order on psychedelic therapies By Investing.com - Investing.com UK
Helus Pharma Inc (HELP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.78%
0.81%
자본화:
|
볼륨(24시간):